Dianthus Therapeutics
DNTH
46 hedge funds and large institutions have $22M invested in Dianthus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 9 closing their positions.
1.09% less ownership
Funds ownership: 48.96% → 47.87% (-1.1%)
12% less funds holding
Funds holding: 52 → 46 (-6)
14% less capital inflows, than outflows
Capital inflows: $6.52M | Capital outflows: $7.58M
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.55M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.38M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
+$391K |
| 4 |
Renaissance Technologies
New York
|
+$62.8K |
| 5 |
CCM
Corsair Capital Management
New York
|
+$47.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
-$3.62M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.29M |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$1.14M |
| 4 |
TCW Group
Los Angeles,
California
|
-$596K |
| 5 |
Morgan Stanley
New York
|
-$356K |
DNTH Hedge Fund Activity: Q2 2023 in Review
46 of the 6,387 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2023, worth a combined $22M — down 6.6% from $23.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of DNTH and 3 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $3.55M. The largest seller was Lion Point Capital, exiting entirely with an estimated $3.62M sold.
- 46 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2023, down from 52 in Q1 2023.
- Funds reported $22M of Dianthus Therapeutics stock for Q2 2023, down 6.6% quarter-over-quarter.
- 3 funds opened new Dianthus Therapeutics positions in Q2 2023 and 9 closed out, a net change of -6 holders.
- The largest Dianthus Therapeutics buyer in Q2 2023 was Nantahala Capital Management, an estimated $3.55M added.
- The largest Dianthus Therapeutics seller in Q2 2023 was Lion Point Capital, an estimated $3.62M sold.
Based on aggregated 13F filings for Q2 2023.